Although the addition of PD-1/PD-L1 inhibitors can to some extent increase the risk of developing pneumonia at all grades, they do not affect the incidence of severe radiation pneumonitis/pneumonia (Grade 3 or higher), and their safety remains within clinically controllable limits. The gene discussed is CD274; the disease is susceptibility to pneumonia measurement.